NEW YORK (GenomeWeb News) — Finnzymes Instruments and Bridge Bioscience have created a joint venture and started a new company to sell certain PCR technologies.
 
Under the agreement, Bridge Bio will transfer all of the physical assets and patents in its PCR business to the new company, called BioInnovations Oy, which will be controlled by Finnzymes.
 
According to BridgeBio’s website, the company’s PCR portfolio includes reagents and products for electroporation, electrophoresis, and transfection.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.